Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASADrugmaker Granules India reported a nearly 60% rise in first-quarter profit on Tuesday as margins improved in its complex generics business.
Consolidated net profit for the quarter ended June 30 rose to 1.8 billion rupees ($18.71 million), compared to 1.13 billion rupees a year earlier, when it had booked a one-time charge.
Total revenue from operations climbed 22% to 14.77 billion rupees on higher sales of finished medicines.
Profit was helped by margin expansion due to a better mix of products sold, the company said, offsetting a 17% increase in expenses.
The drugmaker incurred a one-time charge of 259.1 million rupees in the year-ago period tied to its acquisition of Senn Chemicals and settlement of certain legal cases.
India’s Dr Reddy’s posts worst week in 3 years as semaglutide setback stokes growth fears
Granules accounts for about 30% of the global market for paracetamol and operates 10 manufacturing plants worldwide - seven in India, two in the U.S. and one in Europe.
Analysts at Choice Equity Broking expected revenue to grow on the back of robust demand for its peptide and contract manufacturing drugs, and flagged the company’s oncology launch pipeline and an U.S. FDA approvals as key focus areas for investors.
Shares of the company rose as much as 3.2% after results.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Dr Reddy’s pauses weight loss drug on quality fears | 0 | 7 | 10-07-2026 |
| 2 | Novartis profit beat driven by cost control as patent expiries bite | 0 | 7 | 21-07-2026 |
| 3 | Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman Sachs | 0 | 6 | 09-07-2026 |
| 4 | Why Semaglutide is an inflection point for India’s generics sector? | -2 | 6 | 15-07-2026 |
| 5 | Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit | -2 | 6 | 09-07-2026 |
| 6 | CEAT’s 22% revenue growth masks margin squeeze; ₹1,205-crore expansion raises the stakes | 0 | 7 | 17-07-2026 |
| 7 | Tech Mahindra shares jump on Q1 results; analysts split on valuation | 2 | 6 | 17-07-2026 |
| 8 | CVS shares pop on earnings beat and outlook, as retail pharmacy and insurance units improve | 5 | 7 | 31-07-2025 |
| 9 | CVS shares pop on earnings beat and outlook, as retail pharmacy and insurance units improve | 5 | 7 | 31-07-2025 |
| 10 | Pandemic darlings Moderna, BioNTech are now on two different paths | 0 | 7 | 31-07-2025 |